URGN
UroGen Pharma Ltd.
NASDAQ · Healthcare · Biotechnology · US
$33.48
−0.80%Oct 19, 2026, 12:00 UTC
The U.S. Food and Drug Administration accepted UroGen Pharma Ltd.’s NDA for investigational UGN-103 to treat adults with recurrent LG-IR-NMIBC and set a PDUFA target action date of June 14, 2027.
Source:Aug 20, 2026, 11:00 UTC
UroGen Pharma entered into a strategic collaboration and investment agreement with IntraGel to access its biodegradable sustained-release gel platform and expand its oncology pipeline.
Aug 5, 2026, 00:00 UTC
UroGen Pharma Ltd. reported its Q2 2026 financial results, with total revenue of $72.5 million and a net loss of $14.4 million.
Jul 8, 2026, 12:00 UTC
UroGen Pharma received FDA clearance of its Investigational New Drug application for UGN-501, an investigational oncolytic virus for non-muscle invasive bladder cancer.
Source: